Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel in persistent or recurrent cervical cancer
NCT00041093Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jun 2002
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in cervical squamous cell carcinoma (CSCC), sponsored by GOG Foundation. Primary endpoints: Progression-Free Survival at 5 years, Objective Response Rate at 5 years and 2 more. Started Jun 2002; status: completed.
02
Drugs
docetaxel
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT00041093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041093.